
Two major U.S. health systems say they will not administer the controversial new Alzheimer’s drug Aduhelm. The decisions by the Cleveland Clinic and Mount Sinai’s Health System in New York City are the latest fallout from the U.S. Food and Drug Administration’s widely criticized approval of the Biogen drug on June 7, The New York… read on > read on >